• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, October 15, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Study shows better option for treatment of inoperable anal cancer

Bioengineer by Bioengineer
June 24, 2020
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Vanderbilt University Medical Center

People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.

The results from an international trial, published by the Journal of Clinical Oncology, suggest that carboplatin-paclitaxel become the standard of care for anal cancer, a rare disease that accounts for less than 3% of all gastrointestinal malignancies. The InterAAct trial compared carboplatin-paclitaxel with cisplatin plus 5-flourouracil (5FU).

“The InterAAct trial identifies carboplatin-paclitaxel as the optimal chemotherapy regimen in the first-line setting for inoperable anal cancer,” said lead U.S. investigator Cathy Eng, MD, David H. Johnson Chair in Surgical and Medical Oncology at Vanderbilt University and co-leader of the Gastrointestinal Cancer Research Program at Vanderbilt-Ingram Cancer Center. “Carboplatin-paclitaxel was associated with less toxicity and a trend toward improved survival, which suggests that it should become the standard of care for these patients and the backbone for future phase three trials.”

The overall survival of patients enrolled on the carboplatin-paclitaxel arm of the clinical trial was 20 months compared to 12.3 months for those on the cisplatin-5FU arm. Carboplatin-paclitaxel was associated with significantly less adverse effects (36%) compared to cisplatin-5FU (62%).

The study enrolled 91 patients from the United States, Australia, Germany, Norway and the United Kingdom between December 2013 and November 2017. The International Rare Cancers Initiative formed the Anal Cancer Working Group to design and conduct trials with the goal of providing metastatic anal cancer patients with new treatment strategies.

Patients with inoperable anal cancer have a five-year survival rate of approximately 30%.

Paclitaxel was first documented as a treatment for advanced anal cancer in 2011 and was later combined with carboplatin. Response rates of 69% had led some clinicians to administer it as a first-line treatment, but the cisplatin-5FU regimen had been adopted internationally.

###

The International Rare Cancers Initiative Anal Cancer Working Group, the National Cancer Institute and ECOG-ACRIN Cancer Research Group initiated the clinical trial comparing the two chemotherapies to provide clinician and clinical researchers better guidance about future clinical trial development.

Media Contact
Tommy Wilemon
[email protected]

Related Journal Article

http://dx.doi.org/10.1200/JCO.19.03266

Tags: cancerMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Southern Africa’s Crop Yields Remain Stagnant Despite Climate Trends

October 15, 2025

Human Organ Chip Technology Paves the Way for Pan-Influenza A CRISPR RNA Therapies

October 15, 2025

Scientists Identify X-Chromosome Gene Increasing Women’s Risk for MS and Alzheimer’s

October 15, 2025

Vegan Diet Reduces Insulin Expenses by 27% in Individuals with Type 1 Diabetes, Study Finds

October 15, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1246 shares
    Share 498 Tweet 311
  • New Study Reveals the Science Behind Exercise and Weight Loss

    105 shares
    Share 42 Tweet 26
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    101 shares
    Share 40 Tweet 25
  • Revolutionizing Optimization: Deep Learning for Complex Systems

    92 shares
    Share 37 Tweet 23

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Southern Africa’s Crop Yields Remain Stagnant Despite Climate Trends

Conformity-Aware Model Revolutionizes Self-Supervised Group Recommendations

Human Organ Chip Technology Paves the Way for Pan-Influenza A CRISPR RNA Therapies

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 65 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.